The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies.
 
Jifang Gong
No Relationships to Disclose
 
Chang Liu
No Relationships to Disclose
 
Jun Yao
No Relationships to Disclose
 
Junli Xue
No Relationships to Disclose
 
Jing Dai
No Relationships to Disclose
 
Yinghua Ji
Research Funding - AoSaiKang (Inst); CSPC Pharmaceutical Group (Inst); Hualan Bio (Inst)
 
Ben Markman
No Relationships to Disclose
 
Alison Hiong
No Relationships to Disclose
 
Xiuli Yang
No Relationships to Disclose
 
Rusen Zhao
No Relationships to Disclose
 
Yi Zheng
No Relationships to Disclose
 
Qingshan Li
No Relationships to Disclose
 
Jun Wu
No Relationships to Disclose
 
Minal A. Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - Mary Crowley Research Center, Dallas Texas
 
Mihitha Hashara Ariyapperuma
Research Funding - Adagene; AstraZeneca; BeiGene; Biothera; BMS Norway; LaNova Australia; MSD Oncology
Travel, Accommodations, Expenses - MSD Oncology
 
Gary Edward Richardson
Research Funding - Adagene (Inst); Agenus (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Thera Solutions (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CBT Pharmaceuticals (Inst); ChemoCentryx (Inst); Corvus Pharmaceuticals (Inst); Curon Biopharmaceutical (Inst); D3 Bio (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Fosun Pharma (Inst); Gene Quantum (Inst); Genfleet Therapeutics (Inst); ImmunGen Inc (Inst); Imugene (Inst); InventisBio (Inst); Janssen Oncology (Inst); Keythera Pharmaceuticals (Inst); LaNova Australia (Inst); Medicenna (Inst); Merck (Inst); Minghui Pharmaceutical (Inst); Neoleukin Therapeutics (Inst); Novotech (Inst); Pfizer (Inst); PharmAbcine (Inst); RemeGen (Inst); Roche/Genentech (Inst); Seagen (Inst); Senz Oncology (Inst); Shanghai Henlius Biotech (Inst); Shanghai Henlius Biotech (Inst); Surface Oncology (Inst); Suzhou Alphamab (Inst); Takeda (Inst); Therapim (Inst); Zentalis (Inst)
 
Xia Qin
Employment - LaNova Medicines Limited
 
Crystal Ying Qin
Employment - LaNova Medicines Limited
Leadership - LaNova Medicines Limited
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)